Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Shanghai Bio-Heart Biological Technology Co., Ltd. Class H ( (HK:2185) ) has shared an announcement.
Shanghai Bio-Heart Biological Technology Co., Ltd. has announced the termination of its 2022 H Share Incentive Scheme, along with the repurchase and cancellation of H shares, and a reduction in registered share capital. This decision, aimed at reducing administrative costs, will not impact the company’s public float or operational performance. The company plans to handle the repurchase and cancellation process in compliance with relevant regulations, pending shareholder approval at the upcoming annual general meeting.
More about Shanghai Bio-Heart Biological Technology Co., Ltd. Class H
Shanghai Bio-Heart Biological Technology Co., Ltd. is a joint stock company based in China, operating in the biotechnology sector. The company focuses on developing and providing biological technology solutions, though specific products or services are not detailed in the announcement.
Average Trading Volume: 358,571
Technical Sentiment Signal: Buy
Current Market Cap: HK$1.06B
For detailed information about 2185 stock, go to TipRanks’ Stock Analysis page.